Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2852W HIGH $7.04
Volume
38.07 K
Value Traded
47.51 K
Short % Float
0.84%
+0.68%Week
-24.23%1 Month
+3.52%3 Month
-26.13%6 Month
-98.73%5 Year
-99.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
49.80 M
EPS (TTM)
-1.06
P/E Ratio
-
Ent. Value
40.19 M
Total Shares
33.99 M
Float Shares
8.81 M
Insiders
74.09%
Institutions
11.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
DWTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Dogwood Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dogwood Therapeutics, Inc.
164Total events
10Upcoming
40Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteHalneuronTrial
Dogwood completes enrollment of 239 patients in Halneuron Phase 2b CINP trial
Chemotherapy Induced Neuropathic Pain (CINP)source ↗
▲Interim AnalysisHalneuronTrial
Positive interim results from Phase 2b CINP trial
chemotherapy induced neuropathic painsource ↗
▲Enrollment CompleteHalneuronTrial
Enrollment completed with 217 patients in Halneuron Phase 2b CINP study
Chemotherapy Induced Neuropathic Painsource ↗
▲IND ClearanceSP16IND
FDA granted IND approval for SP16
Chemotherapy Induced Pain and Peripheral Neuropathysource ↗
▲Trial InitiationHalneuronTrial
Phase 2b long-term extension study commenced
Chemotherapy Induced Neuropathic Painsource ↗
▲Partnership / LicenseCorporate
Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets
▲Enrollment MilestoneHalneuronTrial
Enrolled first 200 patients in Phase 2b CINP trial
chemotherapy induced neuropathic painsource ↗
◆Topline ReadoutHalneuronClinical Data
Top-line results for Halneuron Phase 2b CINP trial expected in fall 2026
Chemotherapy Induced Neuropathic Painsource ↗
▲OLE InitiatedHalneuronTrial
Commencement of Halneuron CINP Phase 2b long term extension study
chemotherapy induced neuropathic painsource ↗
▲Interim AnalysisHalneuronTrial
Pre-planned interim analysis supported continuation of double-blinded Phase 2b study
chemotherapy induced neuropathic painsource ↗
▲IND ClearanceSP16IND
FDA acceptance of SP16 Investigational New Drug Application
Chemotherapy Induced Pain and Neuropathysource ↗
▲Partnership / LicenseCorporate
Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets
▲Partnership / LicenseCorporate
Dogwood Therapeutics announces global development and commercialization partnership with PRIDCor for IMC-1 and IMC-2
▲IND ClearanceSP16IND
FDA acceptance of SP16 IND for CIPPN
chemotherapy-induced pain and peripheral neuropathysource ↗
◆First Patient DosedSP16Trial
Patient enrollment expected to commence in middle of 2026
chemotherapy-induced pain and peripheral neuropathysource ↗
◆Full ResultsHalneuronClinical Data
Full results from Phase 2b trial
Chemotherapy-Induced Neuropathic Painsource ↗
◆Enrollment UpdateHalneuronTrial
Recruited 143 patients in ongoing Halneuron Phase 2b trial
chemotherapy-induced neuropathic pain (CINP)source ↗
◆Trial InitiationHalneuronTrial
Commencement of Phase 2b extension trial
chemotherapy-induced neuropathic pain (CINP)source ↗
▲Enrollment MilestoneHalneuronTrial
50% enrollment achieved in Phase 2b trial
chemotherapy induced neuropathic painsource ↗
▼Equity OfferingCorporate
Pricing of $12.5 million registered direct offering and concurrent private placement with potential additional $14.4 million from warrants
▼Equity OfferingCorporate
Financing providing operational runway through Phase 2b final data readout
●Runway Guidance UpdateCorporate
Cash on hand of $10.1 million provides operational runway through Q1 2026
◆First Patient DosedSP16Trial
Projected patient enrollment beginning in first half of 2026 for SP16 IV Phase 1b CIPN study
chemotherapy-induced peripheral neuropathy (CIPN)source ↗
▲Interim AnalysisHalneuronTrial
Positive interim analysis results from Phase 2b CINP study
chemotherapy induced neuropathic painsource ↗
●Composition Patent FiledHalneuronIP / Competition
Filed new composition of matter IP for synthetic Halneuron
▲Interim AnalysisHalneuronTrial
Independent statistical review committee reviewed unblinded data and concluded Halneuron patients showing separation from placebo
chemotherapy induced neuropathic painsource ↗
▲Enrollment UpdateHalneuronTrial
Enrolled 100 patients, 80 completed treatment in Halneuron Phase 2b trial
chemotherapy-induced neuropathic pain (CINP)source ↗
▲Partnership / LicenseSP16Corporate
Secured exclusive worldwide royalty-free license to develop and commercialize SP16
cancer-related painsource ↗
◆Oral PresentationHalneuronPresentation
Halneuron Program Overview at 19th Annual Pain Summit
CINPsource ↗
◆Interim AnalysisHalneuronTrial
Interim data analysis from Halneuron Phase 2 CINP study
Chemotherapy Induced Neuropathic Painsource ↗
▲Fast Track DesignationHalneuronDesignation
FDA Fast Track Designation for Treatment of CINP
CINPsource ↗
◆Enrollment MilestoneHalneuronTrial
Goal to recruit 100 patients with CINP by Q4 2025
chemotherapy-induced neuropathic painsource ↗
▲Partnership / LicenseSP16Corporate
Exclusive worldwide, royalty free license to develop and commercialize SP16 for cancer related pain
cancer related pain (CRP) including chemotherapy induced neuropathysource ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseSP16Corporate
Dogwood licensed SP16 from Serpin Pharma in September 2025
chemotherapy-induced pain and peripheral neuropathysource ↗
●Enrollment UpdateHalneuronTrial
Enrollment to-date of 52 patients in Halneuron Phase 2b trial
Chemotherapy-Induced Neuropathic Painsource ↗
▲Enrollment MilestoneHalneuronTrial
Enrolled first 50 patients in Phase 2b CINP trial
Chemotherapy-Induced Neuropathic Painsource ↗
◆Oral PresentationPresentation
Dogwood Therapeutics CEO presents corporate overview at Sidoti Small-Cap Virtual Conference
▲First Patient DosedHalneuronTrial
First patient dosed in Halneuron CINP Phase 2b study
Chemotherapy Induced Neuropathic Painsource ↗
◆Enrollment UpdateHalneuronTrial
Dosing patients in Halneuron Phase 2b CINP trial
Chemotherapy Induced Neuropathic Painsource ↗
Past FDA Catalysts and PDUFA Decisions
How DWTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Halneuron® | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 59%
Micro Cap(rank 389 of 658)
Percentile Rank
Dogwood Therapeutics, Inc. faces pipeline headwinds (33/100), with $32M risk-adjusted pipeline value, led by Halneuron in Chemotherapy Induced Neuropathic Pain (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Halneuron Small moleculeNCT06848348 | Chemotherapy Induced Neuropathic Pain | Phase 2 | ACTIVE NOT_RECRUITING | 240 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every DWTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Halneuron® Fast Track | chemotherapy-induced neuropathic pain | Phase 2b | 2026-08-17 | positive interim resultsRead More | Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Grosswald RalphOfficer (SVP OF OPERATIONS) | Grant/Award | 82,500 82,500 held | $0.00 | 03/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DWTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DWTX for Q2 2026. | ||||
DWTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DWTX ranks across every disease it competes in
Competitive Position is a premium feature
See how DWTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDWTX News
DWTX▲ +3.9%today
Dogwood to Participate in the 2026 Maxim Growth Summit
Dogwood Therapeutics will participate in the 2026 Maxim Growth Summit from October 12-14 in New York. CEO Greg Duncan will engage with investors and analysts during the event. The company recently completed enrollment in its Halneuron Phase 2b trial, with topline data expected in November 2026. Dogwood focuses on developing non-opioid medicines for pain and neuropathy.
Read more →DWTXDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Dogwood Therapeutics has completed patient enrollment in its Phase 2b trial for Halneuron, targeting chemotherapy-induced neuropathic pain (CINP). The trial enrolled 239 patients, reaching the upper limit of its target range. Topline results are anticipated in November 2026, which could mark a significant advancement in treatment options for CINP, a condition currently lacking FDA-approved therapies.
Read more →DWTXDogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Dogwood Therapeutics is hosting a virtual KOL event on September 1, 2026, to discuss Halneuron® for chemotherapy-induced neuropathic pain. The event will feature expert speakers who will review the treatment landscape and the mechanism of action of Halneuron®. The ongoing Phase 2b trial has shown promising interim results, highlighting the potential of Halneuron® in addressing this painful condition.
Read more →DWTXDogwood Therapeutics Announces Second Quarter 2026 Financial Results
Dogwood Therapeutics reported its second quarter 2026 financial results, highlighting progress in its Halneuron Phase 2b trial for chemotherapy-induced neuropathy, with top-line results expected in fall 2026. The company also announced a long-term extension study and a significant partnership for antiviral assets. However, it faced a notable increase in net loss and impairment charges due to stock price decline.
Read more →DWTXDogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Dogwood Therapeutics has enrolled the first 200 patients in its Phase 2b trial for Halneuron®, aimed at treating chemotherapy-induced neuropathy. The trial has shown a low dropout rate of 4.5%, indicating good tolerability. An independent review has noted positive pain improvement results compared to placebo. Top-line data is anticipated in fall 2026.
Read more →DWTX▼ -9.6%on this news· ran to -22% by day 3
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Dogwood Therapeutics has appointed Iain Dukes, a seasoned biopharma executive, as Chair of its Scientific Advisory Board. Dr. Dukes will guide the company on scientific developments for its innovative pain and neuropathy therapeutics. The company is advancing its lead candidate, Halneuron, into Phase 2b trials, with promising data expected in late 2026.
Read more →DWTX▼ -7.1%on this news
Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics has announced the start of a Phase 2b long-term extension study for Halneuron®, a treatment for chemotherapy-induced neuropathic pain (CINP). The study follows a positive interim analysis that supports continuing the treatment with Halneuron®. Patients who completed the initial 4-week study can enroll for an additional 12-week period, aimed at assessing ongoing safety and effectiveness. This data will be crucial for the planned Phase 3 submission to the FDA, which is projected to commence in 2027.
Read more →DWTX▲ +6.5%on this newsshared move
Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New
Dogwood Therapeutics reported its financial results for the first quarter of 2026, highlighting significant progress in its clinical pipeline. The Phase 2b trial for Halneuron, aimed at treating chemotherapy-induced neuropathy, is on track for results in fall 2026. Additionally, the FDA has accepted the Investigational New Drug Application for SP16. The company also established a worldwide partnership for its antiviral assets, which holds potential value up to $100 million. Overall, Dogwood demonstrates operational strength despite a reported net loss, which is notably lower than the previous year's figures.
Read more →DWTX▼ -5.5%on this news
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Dogwood Therapeutics, a biopharmaceutical company, will report its first quarter 2026 financial results on May 14, 2026. The company focuses on developing treatments for pain and neuropathy, with Halneuron in Phase 2b trials and SP16 IV set for a Phase 1b trial. Both candidates target chemotherapy-induced pain and neuropathic disorders.
Read more →DWTX▼ -8.5%on this news
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics has entered a global partnership with PRIDCor Therapeutics for the development and commercialization of antiviral assets IMC-1 and IMC-2. This agreement includes potential payments up to $100 million and a tiered royalty of up to 15% on net sales. Dogwood will benefit from the financial support while focusing on its lead products, Halneuron® and SP16. However, the success of this partnership is contingent upon PRIDCor's execution of the development plans.
Read more →DWTXDogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood Therapeutics has announced the FDA's acceptance of its Investigational New Drug application for SP16, a treatment targeting chemotherapy-induced pain and neuropathy. This marks a pivotal step for the company as it progresses into clinical trials, with patient enrollment expected to begin in mid-2026 at the University of Virginia. The SP16 candidate has been designed to reduce inflammation and promote tissue repair, addressing the high incidence of chemotherapy-induced peripheral neuropathy. Significant funding for the upcoming trial comes from a $2.5 million grant awarded by the National Cancer Institute.
Read more →DWTX▼ -10%on this news
CEO Letter to Dogwood Therapeutics Shareholders: First Quarter 2026 Progress Report ALPHARETTA, Ga.
Dogwood Therapeutics (DWTX) has provided a corporate update highlighting its advancements in developing non-opioid treatments for cancer-related pain and neuropathy. CEO Greg Duncan expressed optimism regarding the company's pipeline, especially focusing on the lead candidate Halneuron, which is currently in Phase 2b trials and has received FDA fast track designation. The upcoming year is seen as promising for both shareholders and patients as the company works towards executing critical milestones in its development programs. Potential challenges remain due to inherent risks in predicting clinical study outcomes and other uncertainties.
Read more →DWTX▼ -7.8%on this news
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Dogwood Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting notable progress in its clinical trials and reduced expenses. The company successfully recruited 143 patients for its ongoing Halneuron Phase 2b trial and launched a Phase 2b extension trial. Despite a substantial net loss of $35.5 million for the year, it showed an improvement compared to the previous year's loss. Additionally, recent financing is expected to fund operations through key clinical milestones.
Read more →DWTX▲ +5%on this news
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Dogwood Therapeutics has announced that it has surpassed 50% enrollment in its ongoing Phase 2b trial for Halneuron, aimed at treating chemotherapy-induced neuropathic pain. The trial is on track to deliver top line results in Q3 2026. Early data suggests Halneuron is well tolerated, with a low dropout rate, and shows promise in pain improvement compared to placebo.
Read more →DWTXCEO Letter to Dogwood Therapeutics Shareholders: The Year in Review, The Year Ahead
Dogwood Therapeutics has issued a corporate update from CEO Greg Duncan reflecting on the progress made in 2025 and outlining future milestones for 2026. The company focuses on developing non-opioid treatments for cancer-related pain and neuropathy, with promising candidates like Halneuron in Phase 2b development. The letter conveys optimism for the upcoming year and highlights the efforts made to enhance the standard of care for affected patients. However, it also acknowledges inherent risks associated with forward-looking statements.
Read more →DWTX▼ -11.3%on this news
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dogwood Therapeutics, Inc. has announced a financing deal of up to $26.8 million to support the development of its lead product, Halneuron®, through Phase 2b trials. The funding includes a registered direct offering and a private placement, with a total of 4,386,037 shares being issued. The company aims to utilize the proceeds to advance clinical development and strengthen its research portfolio.
Read more →DWTX▼ -25%on this news· ran to -40% by day 1
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dogwood Therapeutics has announced positive interim results from its Phase 2b clinical trial for Halneuron® in treating chemotherapy-induced neuropathic pain (CINP). An independent statistical review highlighted that patients receiving Halneuron® exhibited significant pain improvement compared to those on placebo. The trial featured a low dropout rate of approximately 4.4%, indicating good tolerability. The company anticipates top-line results to be available in Q3 2026 as they push towards potentially groundbreaking developments for CINP therapies.
Read more →DWTXDogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Dogwood Therapeutics has filed for new intellectual property protection for its synthetic Halneuron®, which could extend exclusivity until 2045. The new synthetic manufacturing process aims to enhance production efficiency and lower costs. Halneuron® is currently in Phase 2b development as a non-opioid treatment for chemotherapy-induced neuropathic pain and has received fast track designation from the FDA.
Read more →DWTX▼ -6.5%on this news
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Dogwood Therapeutics reported its Q3 2025 financial results, highlighting the enrollment of 100 patients in the Halneuron® Phase 2b trial. The company secured a worldwide license for SP16, a new treatment for cancer-related pain. Despite a net loss of $15.7 million, Dogwood remains optimistic about upcoming milestones, including an interim analysis in Q4 2025.
Read more →DWTX▼ -12.2%on this news
NASDAQ: DWTX Q4 2025 Update Deep Commitment to Advancing First-in-Class New Therapeutic Treatments for Cancer Patients Suffering from Neuropathy NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 2 Forward-Loo
Dogwood Therapeutics, Inc. is making strides in developing treatments for chemotherapy-induced neuropathy (CINP) with two key programs: Halneuron and SP16. Halneuron, currently in Phase 2b trials, is a Nav1.7 channel blocker that aims to provide effective pain relief from CINP, while SP16, an LRP1 agonist, seeks to offer neuroprotection during chemotherapy. Recent updates highlight the recruitment of patients for the Halneuron study and the filing of new intellectual property for SP16. With NCI funding supporting these initiatives, Dogwood is positioned to advance its therapies towards market entry.
Read more →About Dogwood Therapeutics, Inc.
Headquarters44 MILTON AVENUE, ALPHARETTA, GA, 30009
BIOPHARMAWATCH ELITE PLUS
Trade the next DWTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime